Why did NANO.PA stock jump today?

Heavy buying on EURONEXT and clinical-development optimism drove the stock up to **€27.25**, with volume at **436,333**, roughly **3.29x** average, signalling strong intraday conviction.

What is Meyka AI's rating for NANO.PA stock?

Meyka AI rates NANO.PA **73.79/100** (Grade **B+**), with a **BUY** suggestion. The grade balances sector comparison, growth metrics and forecasts; it is informational only.

What are the short-term targets for NANO.PA stock?

Meyka AI's short-term projections list a **monthly €21.03**, **quarterly €27.44**, and **12-month €25.46**. The quarterly figure is slightly above the intraday price.

What technical risks should traders watch on NANO.PA stock?

Key signals: RSI **77.59** and MFI **81.97** indicate overbought conditions, while ADX **32.55** shows a strong trend; expect possible pullbacks or consolidation.

How do fundamentals affect NANO.PA stock outlook?

Nanobiotix is loss-making with EPS **-1.09** and tight liquidity (current ratio **0.63**), so long-term upside depends on clinical success and funding.

EU Stocks

NANO.PA Nanobiotix S.A. EURONEXT up 18.74% intraday 02 Mar 2026: analyze momentum and risk

ByHuzaifa Zahoor March 2, 2026

NANO.PA stock jumped 18.74% intraday to €27.25 on 02 Mar 2026 after heavy buying pushed volume to 436,333 shares. The move followed a higher open at €25.00 and a day high of €28.35, as traders reacted to clinical-development momentum and repositioning in biotechnology names across EURONEXT. We examine why Nanobiotix S.A. (NANO.PA) is leading top-gainers today, link the price action to fundamentals and technicals, and set short- and medium-term scenarios for investors in Europe.